Related Experiment Video
Updated: Feb 6, 2026
09:22
Chronic Thromboembolic Pulmonary Hypertension and Assessment of Right Ventricular Function in the Piglet
Published on: November 4, 2015
12.6K
Chronic Thromboembolic Pulmonary Hypertension: An Update
Jean M Elwing1, Anjali Vaidya2, William R Auger3
1Pulmonary Hypertension Program, Division of Pulmonary, Critical Care and Sleep Medicine, University of Cincinnati College of Medicine, 231 Albert Sabin Way, ML 0564, Cincinnati, OH 45267, USA.
Clinics in Chest Medicine
|August 21, 2018
Summary
Chronic thromboembolic pulmonary hypertension (CTEPH) is a progressive condition causing pulmonary artery obstruction. Optimal management involves surgical or catheter-based interventions, with medical therapy for inoperable cases.
Area of Science:
- Cardiology
- Pulmonary Medicine
- Vascular Disease
Background:
- Chronic thromboembolic pulmonary hypertension (CTEPH) is a progressive vascular disease with high morbidity.
- It arises from unresolved thromboemboli obstructing pulmonary arteries, leading to pulmonary hypertension (PH).
Purpose of the Study:
- To outline the clinical assessment and management strategies for CTEPH.
- To highlight the importance of expert consultation and specialized interventions.
Main Methods:
- Clinical assessment including pulmonary hemodynamics and radiologic evaluation.
- Consultation with expert centers for diagnosis and treatment planning.
Main Results:
- Surgical intervention is the primary optimal management strategy for CTEPH.
- Balloon pulmonary angioplasty is a viable catheter-based option for select patients.
- Pulmonary hypertension-targeted medical therapy is used for inoperable or post-intervention PH.
Conclusions:
- CTEPH necessitates comprehensive evaluation and specialized care.
- A multidisciplinary approach integrating surgery, interventional procedures, and medical therapy optimizes patient outcomes.
Keywords:
Balloon pulmonary angioplasty (BPA)Chronic thromboembolic disease (CTED)Chronic thromboembolic pulmonary hypertension (CTEPH)Pulmonary endarterectomy (PEA)Pulmonary hypertension (PH)Pulmonary thromboendarterectomy (PTE)More Related Videos
Related Concept Videos
01:30Pulmonary Hypertension: Classification and Pathogenesis
659
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
659
01:24Chronic Obstructive Pulmonary Disease
2.6K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
2.6K
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
615
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
615
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
3.8K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
3.8K
01:29Chronic Obstructive Pulmonary Disease-V: Management
3.2K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
3.2K
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
4.6K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
4.6K